List of insiders holdings for Translate Bio Inc.: 
 - Shares directly owned by the insider.
 - Shares indirectly owned by the insider.
 - Total shares owned by the insider (sum of shares directly and indirectly owned).
 - Total market value if available.
 - Shares are not adjusted for stock split.
 
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
 - Peter Lynch
What is insider trading>>
| # | Insider Holder Name | Report Date Time  | Shares Owned Directly Indirectly  | Total Shares Owned  | Filing | 
| 1 | Sanofi 10% Owner  | 2021-09-14 09:59:09 | 75,668,031 0  | 75,668,031 | Form 4 | 
| 2 | BAUPOST GROUP LLC Baupost Group GP L.L.C. KLARMAN SETH A 10% Owner  | 2021-09-16 17:43:14 | 0 18,044,239  | 18,044,239 | Form 4/A | 
| 3 | Shire Human Genetic Therapies Inc. Shire plc 10% Owner  | 2018-07-02 21:46:18 | 7,262,564 0  | 7,262,564 | Form 4 | 
| 4 | Atlas Venture Fund VIII L.P. Atlas Venture Associates VIII L.P. Atlas Venture Associates VIII Inc. 10% Owner  | 2021-02-02 13:01:00 | 3,922,008 0  | 3,922,008 | Form 13G | 
| 5 | Gallagher Brian M. Jr. Director  | 2018-07-05 16:30:24 | 0 3,697,912  | 3,697,912 | Form 4 | 
| 6 | Omega Fund IV L.P. Omega Fund IV GP L.P. Omega Fund IV G.P. Manager Ltd. Omega Fund V L.P. Omega Fund V GP L.P. Omega Fund V GP Manager Ltd. Stampacchia Otello Lim Richard J. Paster Anne-Mari Nessi Claudio 10% Owner  | 2020-02-14 11:02:06 | 2,437,603 0  | 2,437,603 | Form 13G | 
| 7 | MRL Ventures Fund LLC 10% Owner  | 2018-07-03 18:44:34 | 1,873,503 0  | 1,873,503 | Form 4 | 
| 8 | GLAXOSMITHKLINE PLC 10% Owner  | 2020-02-14 16:40:57 | 646,541 0  | 646,541 | Form 13D | 
| 9 | LYNCH DANIEL Director  | 2021-02-16 16:12:26 | 221,825 0  | 221,825 | Form 5 | 
| 10 | Heartlein Michael Chief Scientific Officer  | 2019-03-12 18:13:27 | 150,000 0  | 150,000 | Form 4 | 
| 11 | Schroer John R. Chief Financial Officer  | 2020-03-05 19:54:54 | 150,000 0  | 150,000 | Form 4 | 
| 12 | Fenton Brian Chief Business Officer  | 2019-03-12 18:12:32 | 90,000 0  | 90,000 | Form 4 | 
| 13 | Barbier Ann Chief Medical Officer  | 2021-03-09 20:24:32 | 70,000 0  | 70,000 | Form 4 | 
| 14 | Wooster Richard Chief Scientific Officer  | 2021-03-09 20:26:10 | 70,000 0  | 70,000 | Form 4 | 
| 15 | Cloghessy Paula Chief Human Resources Officer  | 2019-03-12 18:11:30 | 60,000 0  | 60,000 | Form 4 | 
| 16 | Beckman Daniella Director  | 2021-09-14 19:19:11 | 0 0  | 0 | Form 4 | 
| 17 | FORMELA JEAN FRANCOIS Director  | 2021-09-14 19:23:37 | 0 0  | 0 | Form 4 | 
| 18 | Demetri George Director  | 2021-09-14 19:25:01 | 0 0  | 0 | Form 4 | 
| 19 | Hughes Owen Director  | 2021-09-14 19:26:06 | 0 0  | 0 | Form 4 | 
| 20 | Meyer Robert J. Director  | 2021-09-14 19:27:02 | 0 0  | 0 | Form 4 | 
| 21 | Plenge Robert M Director  | 2021-09-14 19:28:19 | 0 0  | 0 | Form 4 | 
| 22 | Burgess Paul D. Chief Operating Officer, CLO  | 2021-09-14 19:29:46 | 0 0  | 0 | Form 4 | 
| 23 | Renaud Ronald C JR Chief Executive Officer  | 2021-09-14 19:32:44 | 0 0  | 0 | Form 4 | 
| 24 | Smith Brendan Chief Financial Officer  | 2021-09-14 19:33:46 | 0 0  | 0 | Form 4 | 
| 25 | Sutherland Everett Rand President  | 2021-09-14 19:34:57 | 0 0  | 0 | Form 4 | 
| 26 | Shire Human Genetic Therapies Inc. TAKEDA PHARMACEUTICAL CO LTD 10% Owner  | 2021-01-25 06:07:39 | 0 0  | 0 | Form 13G |